Myelin Repair Foundation Teams With Academia To Find Therapies That Can Halt MS
Executive Summary
The non-profit group has funded basic research on two multiple sclerosis treatments now in Phase I trials and has agreements with four pharma companies to run assay tests of their compounds.
You may also be interested in...
Sanofi Takes Another Step Forward In MS, Files Lemtrada NDA
Sanofi is seeking a six-month priority review for the multiple sclerosis drug Lemtrada, positioning it for a potential launch by the end of the year. Meanwhile, FDA action on Aubagio is expected in June.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.